comparemela.com


Search jobs
Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited
Osaka, Japan, April 1, 2021 --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the asset transfer associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”) for JPY 133.0 billion
®, Liovel
® and Zafatek
®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019. While the products included in the asset transfer continue to play important roles in meeting patient needs in the country, they were outside of Takeda’s chosen business areas – Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience – core to its global long-term growth strategy. The transaction continues Takeda’s strong momentum toward optimizing its portfolio for growth by discovering and delivering life-transforming treatments in its focused key business areas.

Related Keywords

Osaka ,Japan ,Teijin Pharma ,Takeda Pharmaceutical Company Limited ,Japan To Teijin Pharma Limited ,Teijin Pharma Limited ,Rare Diseases ,Plasma Derived Therapies ,Fiscal Year ,Reported Profit ,Net Profit ,Core Operating Profit ,Score Net ,Full Year Consolidated Financials ,ஒசகக ,ஜப்பான் ,டாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவை ,ரேர் நோய்கள் ,நிதி ஆண்டு ,நிகர ப்ராஃபிட் ,கோர் இயங்குகிறது ப்ராஃபிட் ,கோர் நிகர ,முழு ஆண்டு தொகுக்கப்பட்டு நிதி ,

© 2024 Vimarsana

comparemela.com © 2020. All Rights Reserved.